References
- El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5 (1): 87–107.
- Blum HE. Hepatocellular carcinoma: therapy and preven- tion. World J Gastroenterol2005; 11 (47): 7391–400.
- Hebbar M, Ernst 0, Caftan S et al. Phase II trial of doc-etaxel therapy in patients with advanced hepatocellular card-noma. Oncology 2006; 70 (2): 154–158.
- Therasse P, Arbuck SG, Eisenhauer EA et al. New guide-lines to evaluate the response to treatment in solid tumors. Eu-ropean Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3): 205–216.
- Olweny CL, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK. Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 1980; 46 (12): 2717–2722.
- Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975; 36 (4): 1250–1257.
- Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40 (3): 225–235.
- O'Reilly EM, Stuart KE, Sanz-Altamira PM et al. A phase II study of irinotecan in patients with advanced hepatocellular car-cinoma. Cancer 2001; 91 (1): 101–105.
- Wall JG, Benedetti JK, O'Rourke MA, Natale RB, Mac-donald JS. Phase II trial to topotecan in hepatocellular carci-noma: a Southwest Oncology Group study. Invest New Drugs 1997; 15 (3): 257–260.
- Ulrich-Pur H, Kornek GV, Fiebiger W, Schull B, Raderer M, Scheithauer W. Treatment of advanced hepatocellular carci-noma with biweekly high-dose gemcitabine. Oncology 2001; 60 (4): 313–315.
- Lencioni M, Falcone A, Allegrini G et al. Oral doxifluri-dine in advanced hepatocellular carcinoma: A phase II study. On-cology 2000; 59 (3): 204–209.
- Chao Y, Chan WK, Birkhofer MJ et al. Phase II and phar-macokinetic study of paclitaxel therapy for unresectable hepato-cellular carcinoma patients. Br J Cancer 1998; 78 (1): 34–39.
- Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with re-active oxygen species. Cancer 2000; 89 (5): 983–994.
- Zhang H, Ozaki I, Mizuta T et al. Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mi-togen-activated protein kinase dependent pathway. Cancer 2002; 95 (4): 896-906.
- Geng CX, Zeng ZC, Wang JY. Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. World J Gastroenterol 2003; 9 (4): 696–700.
- Sutter AP, Maaser K, Grabowski P et al. Peripheral ben-zodiazepine receptor ligands induce apoptosis and cell cycle ar-rest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J Hepatol 2004; 41 (5): 799-807.
- Ishikawa T, Ichida T, Yokoyama J, Matsuda Y, Watanabe T, Asakura H. Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy. J Gastroenterol Hepatol 2004; 19 (12): 1423–1426.
- Ryan DP, Lynch TJ, Grossbard ML et al. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tu-mors. Cancer 2000; 88 (1): 180–185.
- Gornet JM, Azoulay D, Duclos-Vallee JC, Goldwasser F. Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. Anticancer Drugs 2000; 11 (8): 649–652.
- Llovet J, Ricci S, Mazzaferro V et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma: Results of a Phase III randomized placebo-controlled trial (SHARP trial). Pro-ceedings from the 2007 annual meeting of the American Soci-ety of Clinical Oncology. Late-breaking Abstract (LBA) #1